Search

Displaying results 9161 - 9170 of 9220 in total
  1. Drug

    TCB-008

    go.drugbank.com/drugs/DB18352
    Investigational

    TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.

  2. Drug

    MDR-101

    go.drugbank.com/drugs/DB18513
    Investigational

    MDR-101 is a CD34+ hematopoietic stem and progenitor cells with CD3+ T-cells

  3. Drug

    FCR001

    go.drugbank.com/drugs/DB18595
    Investigational

    FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.

  4. Drug

    WU-CART-007

    go.drugbank.com/drugs/DB18617
    Investigational

    WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.

    Synonyms: an allogeneic, fratricide-resistant genetically modified T cell transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7
  5. Drug

    Prizloncabtagene autoleucel

    go.drugbank.com/drugs/DB18623
    Investigational

    C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.

    Synonyms: autologous T lymphocytes obtained from peripheral blood lymphocytes by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector, encoding a bispecific chimeric antigen receptor, an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR
  6. Drug

    CTX120

    go.drugbank.com/drugs/DB18625
    Investigational

    CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.

    Synonyms: allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting B-cell maturation antigen
  7. Drug

    CTX110

    go.drugbank.com/drugs/DB18626
    Investigational

    CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.

    Synonyms: allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD19 antigen
  8. Drug

    Zedenoleucel

    go.drugbank.com/drugs/DB18639
    Investigational

    MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.

  9. Drug

    ALLO-715

    go.drugbank.com/drugs/DB18640
    Investigational

    ALLO-715 is an allogeneic chimeric antigen receptor T Cell therapy targeting B cell maturation antigen (BCMA).

    Synonyms: Allogenic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen (BCMA)
  10. Drug

    Lacutamab

    go.drugbank.com/drugs/DB15322
    Investigational

    Lacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)).